Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. (PFE) is launching a Phase 1 study called “A PHASE 1, OPEN-LABEL, RANDOMIZED, CROSSOVER, SINGLE DOSE, PIVOTAL BIOEQUIVALENCE STUDY TO COMPARE TAFAMIDIS FREE ACID TABLET AND COMMERCIAL TAFAMIDIS FREE ACID CAPSULE ADMINISTERED UNDER FED CONDITIONS IN HEALTHY ADULT PARTICIPANTS.” The goal is to see if a new tafamidis tablet matches the exposure of the current capsule in the blood, which matters for future labeling, pricing, and supply strategy.
The trial tests two oral forms of tafamidis, a key Pfizer drug for transthyretin amyloidosis (ATTR-PN). One is the existing 61 mg free acid capsule and the other is a new 61 mg free acid tablet, both aimed at delivering the same amount of active drug in the body.
This is an interventional Phase 1 trial in healthy adults with a randomized crossover design. Each person receives both the reference capsule and the test tablet at different times, with no blinding, and the main aim is basic science bioequivalence rather than direct patient benefit.
The study is listed as not yet recruiting with first submission on 10 March 2026 and last update on the same date, signaling early setup. Primary and final completion dates are not posted yet, but Phase 1 crossover bioequivalence studies typically run on a short timeline once enrollment begins.
For investors, a positive outcome could support smoother lifecycle management of Pfizer’s tafamidis franchise, potentially lowering manufacturing costs and improving flexibility without changing efficacy. This matters as tafamidis faces rising scrutiny on price and growing competition in ATTR from firms such as Alnylam and Ionis, so efficient formulations can help defend share even if they do not add new revenue streams.
The study is currently in the startup phase and remains active in the registry, with further details and updates available on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.